RANKL/PD-1 dual blockade demonstrates survival benefit for patients with advanced lung adenocarcinoma harboring KRAS mutations.
RANKL/PD-1 双重阻断疗法可提高携带 KRAS 突变的晚期肺腺癌患者的生存率
期刊:Cell Reports Medicine
影响因子:10.6
doi:10.1016/j.xcrm.2025.102235
Li Hong-Shuai, Liu Cheng-Ming, Zheng Su-Fei, Wu Peng, Xu Han-Yan, Hao Xue-Zhi, Li Jun-Ling, Xing Pu-Yuan, Duan Jian-Chun, Wang Zhi-Jie, Zhong Jia, Tian Lin-Yan, Cui Yan-Yan, Fang Qin, Lei Si-Yu, Wang Si-Hui, Luo Yue-Jun, Wang Zhan-Yu, Wang Jie, He Jie, Sun Nan, Wang Yan
